While the data presented in this study were derived from in vitro experiments, the in vivo relevance of this relationship could be appreciated in the recent report that the targeting of Lrig1, a negative regulator of Egf/ErbB receptor signaling, in a Lrig1+ve stem cell population resulted in increased Egfr and Lgr5 expression in vivo and intestinal tumors [12]. The gene discussed is LGR5; the disease is intestinal neoplasm.